Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD2820
- Development stage
- Discontinued
- Lead developer
- AstraZeneca
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
AZD2820 is a synthetic peptide drug developed by AstraZeneca as a potential treatment for obesity. It acts as an agonist of the melanocortin 4 receptor (MC4R), a receptor in the brain involved in regulating appetite and energy homeostasis. By weakly activating MC4R, AZD2820 suppresses appetite and was investigated for its ability to induce weight loss in obese individuals. The drug was administered via subcutaneous injection and underwent phase I clinical trials to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy volunteers and obese men. Development of AZD2820 has since been discontinued[3][5][7].
02
Targets
MC3R (Melanocortin Receptor Type 3)MC4R (Melanocortin 4 receptor)
Beyond the preview
Go deeper on AZD2820.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD2820.